Novartis Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune ® Oral Solution (Cyclosporine Oral Solution, USP), 100 mg/mL Due to Crystallization
Novartis is conducting a voluntary nationwide recall at the consumer level of two lots of its Sandimmune ® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL in the US due to crystal formation observed in some bottles, which could potentially result in incorrect dosing. The issue was identifi (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 27, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Novartis Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune(R) Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization
EAST HANOVER, N.J., Nov. 24, 2023 -- (Healthcare Sales & Marketing Network) -- Novartis is conducting a voluntary nationwide recall at the consumer level of two lots of its Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL in the ... Biopharmaceuticals, Product Recall Novartis, Sandimmune, cyclosporine, organ transplant (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 24, 2023 Category: Pharmaceuticals Source Type: news
Novartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune ® Oral Solution (Cyclosporine Oral Solution, USP), 100 mg/mL Due to Crystallization
Novartis is conducting a voluntary nationwide recall at the consumer level of one lot of its Sandimmune ® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL in the US due to crystal formation observed in some bottles, which could potentially result in incorrect dosing. No other Sandimmune for (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 11, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Approves Second Waterless Solution for Dry Eye Disease FDA Approves Second Waterless Solution for Dry Eye Disease
The new water-free cyclosporine-based solution is intended to treat the signs and symptoms of dry eye disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 9, 2023 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news
FDA Approves Vevye (cyclosporine) Ophthalmic Solution for the Treatment of the Signs and Symptoms of Dry Eye Disease
Heidelberg, Germany and Cambridge, MA, USA, June 8, 2023– Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 8, 2023 Category: Drugs & Pharmacology Source Type: news
Water-Free Cyclosporine Eye Drop, 0.1 Percent, Effective for Dry Eye
MONDAY, April 10, 2023 -- A water-free cyclosporine solution is effective for treating moderate-to-severe dry eye disease (DED), according to a study published online April 6 in JAMA Ophthalmology.
Esen K. Akpek, M.D., from Johns Hopkins University... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 10, 2023 Category: Pharmaceuticals Source Type: news
Baricitinib Reduces Signs, Symptoms of Cyclosporine-Resistant AD Baricitinib Reduces Signs, Symptoms of Cyclosporine-Resistant AD
Baricitinib 4 mg met the primary endpoint in a phase 3 study involving patients with AD who had failed or could not take cyclosporine.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - August 11, 2022 Category: Internal Medicine Tags: Dermatology News Source Type: news
Management of Atopic Dermatitis: Bringing Therapy Into Focus Management of Atopic Dermatitis: Bringing Therapy Into Focus
Saakshi Khattri, MD, recounts the evolution of treatments for atopic dermatitis (AD), from the widespread use of general immune suppressants such as methotrexate and cyclosporine, to more recent, targeted agents.Medscape (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 29, 2022 Category: Allergy & Immunology Tags: Dermatology MDAngle Source Type: news
Sandimmune (Cyclosporine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2022 Category: Drugs & Pharmacology Source Type: news
FDA Approves First Generic Version of Restasis for Dry Eye FDA Approves First Generic Version of Restasis for Dry Eye
The brand name medicated eyedrops have been available in the United States for nearly 20 years.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 3, 2022 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Sun Pharma launches dry eye treatment product in Canada
The product is the first dry eye treatment available in Canada that is delivered with nanomicellar (NCELL) technology, which improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration, Sun Pharma said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 27, 2022 Category: Pharmaceuticals Source Type: news
NLM Technical Bulletin, Nov-Dec 2021, RxNorm November 2021 Release
The RxNorm November monthly release became available for download on Monday, November 1, 2021, and contains a new concept for Restasis single-use vials (RXCUI 2572293). (Source: NLM Technical Bulletin)
Source: NLM Technical Bulletin - November 1, 2021 Category: Databases & Libraries Source Type: news
FDA Approves Verkazia (cyclosporine ophthalmic emulsion) for the Treatment of Vernal Keratoconjunctivitis
EMERYVILLE, Calif.--(BUSINESS WIRE) June 24, 2021 --Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), a global company focused exclusively on eye care, today announced that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 24, 2021 Category: Drugs & Pharmacology Source Type: news
Study identifies possible COVID-19 drugs -- including several that are FDA-approved
(University of Pennsylvania School of Medicine) Of the nine drugs found to reduce SARS-CoV-2 replication in respiratory cells, three already have FDA approval: the transplant-rejection drug cyclosporine, the cancer drug dacomitinib, and the antibiotic salinomycin. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 2, 2021 Category: Infectious Diseases Source Type: news
Sandimmune (cyclosporine)
Title: Sandimmune (cyclosporine)Category: MedicationsCreated: 3/12/2021 12:00:00 AMLast Editorial Review: 3/12/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - March 12, 2021 Category: Rheumatology Source Type: news
